Drugs / Nimustine
Nimustine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02698280 | Jul 2015 → Jan 2018 | glioblastoma | Huashan Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nimustine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02698280 ↗ |
| Known as | Nimustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL136737 ↗ |
| Known as | NIMUSTINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL136737 ↗ |
| Known as | NSC-758675 | ChEMBL registry synonym — accepted as the source's own label CHEMBL136737 ↗ |
| Modality | Small molecule | — CHEMBL136737 ↗ |
| Route | Intravenous | “Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.” NCT02698280 ↗ |